Advertisement

General Thoracic and Cardiovascular Surgery

, Volume 60, Issue 1, pp 1–12 | Cite as

Thymoma and thymic carcinoma

  • Federico VenutaEmail author
  • Erino A. Rendina
  • Marco Anile
  • Tiziano de Giacomo
  • Domenico Vitolo
  • Giorgio F. Coloni
Guest Review Article

Abstract

Thymic tumors comprise a heterogeneous group of neoplasms with a wide spectrum of clinical presentations. The evolution of the disease is often unpredictable, ranging from an indolent attitude to the possibility of intra- and extrathoracic spread. From the histological point of view, thymoma and thymic carcinoma are the most frequent subtypes and arise only from thymic epithelial cells. Other histological types are even more rare and are usually considered separately. A number of prognostic factors have been validated as predictors of outcome: staging, World Health Organization histological classification, diameter of the tumor, associated paraneoplastic syndromes, completeness of resection, and early onset of recurrence. Complete surgical resection is the key factor for cure and should be considered the gold standard at any stage. Especially for more aggressive lesions, surgery should be considered with a multimodality approach, involving induction and adjuvant therapy according to the stage. Multimodality therapy protocols have been designed based on the integration of clinical staging and histology. Neoadjuvant therapy is now administered before surgical resection in patients with tumors considered inoperable as it improves resectability and survival and reduces the risk of recurrence. Adjuvant treatment has been extensively reported after both complete or partial resection. New targeted therapies are in the developmental stage, and in the future they will be part of the standard protocols. Integrated treatment modalities require strict cooperation between medical and radiation oncologists, thoracic surgeons, and pathologists.

Key words

Thymoma Thymic carcinoma Mediastinal tumors Myasthenia gravis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Onco 2010;5:S260–S265.CrossRefGoogle Scholar
  2. 2.
    Nakahara K, Ohno K, Hashimoto L, Maeda H, Miyoshi S, Sakurai M, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg 1988;95:1041–1047.PubMedGoogle Scholar
  3. 3.
    Patton DF, Ribeiro RC, Jenkins JJ, Sixbey JW. Thymic carcinoma with defective Epstein-Barr virus encoding the BZLF1 trans-activator. J Infect Dis 1994;170:7–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu TC, Kuo TI. Study of Epstein Barr virus early RNA 1 (EBER1) expression by in situ hybridization in thymic epithelial tumors of Chinese patients in Taiwan. Hum Pathol 1993;24:235–238.PubMedCrossRefGoogle Scholar
  5. 5.
    Li H, Loehrer PJ Sr, Hisada M, Henley J, Whitby D, Engels EA, et al. Absence of human T cell lymphocytic virus type 1 and human foamy virus in thymoma. Br J Cancer 2004;90:2181–2185.PubMedCrossRefGoogle Scholar
  6. 6.
    Saib A, Canivet M, Giron ML, Bolgert F, Valla J, Lageye S, et al. Human foamy virus infection in myasthenia gravis. Lancet 1994;343:666.PubMedCrossRefGoogle Scholar
  7. 7.
    Verley JM, Hollman KH. Thymoma: a comparative study of clinical stages, histologic features and survival in 200 cases. Cancer 1985;55:1074–1086.PubMedCrossRefGoogle Scholar
  8. 8.
    Regnard JF, Magdeleinat P, Dromer C, Dulmet E, de Montpreville V, Levi JF, et al. Prognostic factors and long term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996;112:376–384.PubMedCrossRefGoogle Scholar
  9. 9.
    Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg 1991;51:152–156.PubMedCrossRefGoogle Scholar
  10. 10.
    Venuta F, Rendina EA, De Giacomo T, Della Rocca G, Antonini G, Ciccone AM, et al. Thymectomy for myasthenia gravis: a 27-year experience. Eur J Cardiothorac Surg 1999;15:621–624.PubMedCrossRefGoogle Scholar
  11. 11.
    Pescarmona E, Rendina EA, Venuta F, D’Arcangelo E, Pagani M, Ricci C, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 1990;50:534–538.PubMedCrossRefGoogle Scholar
  12. 12.
    Salyer WR, Eggleston JC, Thymoma: a clinical and pathologic study of 65 cases. Cancer 1976;37:229–249.PubMedCrossRefGoogle Scholar
  13. 13.
    Chan JK, Rosai J. Tumors of the neck showing thymic or related to bronchial pouch differentiation: a unifying concept. Hum Pathol 1991;22:349–367.PubMedCrossRefGoogle Scholar
  14. 14.
    Yanagawa M, Tomiyama N. Prediction of thymoma histology and stage by radiographic criteria. Thorac Surg Clin 2011;21:1–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA, et al. 18FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006;47:1628–1634.PubMedGoogle Scholar
  16. 16.
    Demura Y, Tsuchida T, lshizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540–548.PubMedGoogle Scholar
  17. 17.
    Rendina EA, Venuta F, De Giacomo T, Ciccone AM, Moretti MS, Ibrahim M, et al. Biopsy of anterior mediastinal masses under local anesthesia. Ann Thorac Surg 2002;74:1720–1722.PubMedCrossRefGoogle Scholar
  18. 18.
    Welsh JS, Wilkins KB, Green R, Bulkley G, Askin F, Diener-West M, et al. Association between thymoma and second neoplasms. JAMA 2000;283:1142–1143.PubMedCrossRefGoogle Scholar
  19. 19.
    Pan C, Chen PC, Wang L, Chi KH, Chiang S. Thymoma is associated with an increased risk of secondary malignancy. Cancer 2001;92:2406–2411.PubMedCrossRefGoogle Scholar
  20. 20.
    Patella M, Anile M, Vitolo D, Venuta F. Synchronous B3 thymoma and lung bronchoalveolar carcinoma. Interact Cardiovasc Thorac Surg 2011;12:75–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Roberts PF, Venuta F, Rendina EA, De Giacomo T, Coloni GF, Follette DM, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001;122:562–568.PubMedCrossRefGoogle Scholar
  22. 22.
    Masaoka A, Yamakawa Y, Niwa H, Fukai I, Saito Y, Tokudome S, et al. Thymectomy and malignancy. Eur J Cardiothorac Surg 1994;8:251–253.PubMedCrossRefGoogle Scholar
  23. 23.
    Yamakawa Y, Masaoka A, Hashimoto T, Niwa N, Mizuno T, Fujii Y, et al. A tentative tumor-node metastasis classification of thymoma. Cancer 1991;68:1984–1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Masaoka A, Monden Y, Nakahara K, Tanioke T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485–2492.PubMedCrossRefGoogle Scholar
  25. 25.
    Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non invasive thymoma. Pathol Int 1994;44:359–367.PubMedCrossRefGoogle Scholar
  26. 26.
    Gamondes JP, Balawi A, Greenland T, Adleine P, Mornex JF, Zhang J, et al. Seventeen years of surgical treatment of thymoma: factors influencing survival. Eur J Cardiothorac Surg 1991;5:124–131.PubMedCrossRefGoogle Scholar
  27. 27.
    Kornstein MJ, Curren WJ, Turrisi AT, Brooks JJ. Cortical versus medullary thymoma: a useful morphologic distinction? Hum Pathol 1988;19:1335–1339.PubMedCrossRefGoogle Scholar
  28. 28.
    Haniuda M, Morimoto M, Nishimura H, Kobayashi O, Yamenda T, Lida F. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 1992;54:311–315.PubMedCrossRefGoogle Scholar
  29. 29.
    Okumura M, Miyoshi S, Takeuchi Y, Yoon HE, Minemi M, Takeda SI, et al. Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg 1999;117:605–613.PubMedCrossRefGoogle Scholar
  30. 30.
    Wilkins KB, Sheikh E, Green R, Patel M, George S, Takano M, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562–574.PubMedCrossRefGoogle Scholar
  31. 31.
    Pescarmona E, Rendina EA, Venuta F, Ricci C, Ruco LP, Baroni CD. The prognostic implication of thymoma histologic subtyping: a study of 80 consecutive cases. Am J Clin Patho 1990;93:190–195.Google Scholar
  32. 32.
    Ruffini E, Mancuso M, Oliaro A, Casadio C, Cavallo A, Cianci R, et al. Recurrence of thymoma: analysis of clinicopathological features, treatment and outcome. J Thorac Cardiovasc Surg 1997;113:55–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumara A, Maeda H, et al. The World Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94:624–632.PubMedCrossRefGoogle Scholar
  34. 34.
    Nakagawa K, Asamura H, Matsumo Y, Suzuki K, Kondo H, Maeshima A, et al. Thymoma: a clinicopathological study based on a new World Health Organization classification. J Thorac Cardiovasc Surg 2003;126:1134–1140.PubMedCrossRefGoogle Scholar
  35. 35.
    Monden Y, Nakahara K, Lioka S, Nonjo S, Ohno K, Fujii Y, et al. Recurrence of thymoma: clinicopathological features, therapy and prognosis. Ann Thorac Surg 1985;39:165–169.PubMedCrossRefGoogle Scholar
  36. 36.
    Ricci C, Rendina EA, Pescarmona E, Venuta F, Di Tolla R, Baroni CD. Correlations between histological type, clinical behavior and prognosis in thymoma. Thorax 1989;44:455–460.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernatz PE, Harrison EG, Clagett OT. Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg 1961;42:424–444.PubMedGoogle Scholar
  38. 38.
    Kirchner T, Marino M, Muller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Pathol 1989;l0:167–189.Google Scholar
  39. 39.
    Rosai J, Sobin L. Histological typing of tumors of the thymus. In: Rosai J, Sobin L, editors. World Health Organization, international classification of tumors. Berlin: Springer; 1999. p. 9–14.Google Scholar
  40. 40.
    Chen G, Marx A, Wen-Hu C, Yong Y, Puppe B, Stroebel P, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420–429.PubMedCrossRefGoogle Scholar
  41. 41.
    Venuta F, Rendina EA, Pescarmona E, De Giacomo T, Vegna ML, Fazi P, et al. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg 1997;64:1585–1592.PubMedCrossRefGoogle Scholar
  42. 42.
    Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, et al. Long term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76:1866–1872.PubMedCrossRefGoogle Scholar
  43. 43.
    Marino M, Muller Hermelink HK. Thymoma and thymic carcinoma: relation of thymoma epithelial cells to the cortical and medullary differentiation of the thymus. Virchows Arch Pathol Anat Histopathol 1985;407:119–149.CrossRefGoogle Scholar
  44. 44.
    Suster S, Moran CA. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma: a clinicopathologic study. Am J Surg Pathol 1996;20:1469–1480.PubMedCrossRefGoogle Scholar
  45. 45.
    Pescarmona E, Rendina EA, Venuta F, Ricci C, Baroni CD. Recurrent thymoma: evidence for histological progression. Histopathology 1995;27:445–449.PubMedCrossRefGoogle Scholar
  46. 46.
    Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin North Am 2008;22:381–392.PubMedCrossRefGoogle Scholar
  47. 47.
    Jackson MA, Ball DL. Postoperative radiotherapy in invasive thymoma. Radiother Oncol 1991;21:77–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Wright CD, Wain JC, Wong DR, Donohue DM, Gaissert HA, Grillo HC, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg 2005;130:1413–1421.PubMedCrossRefGoogle Scholar
  49. 49.
    Bernatz PE, Khonsari S, Harrison EG Jr, Taylor WF. Thymoma: factors influencing prognosis. Surg Clin North Am 1973;53:885–892.PubMedGoogle Scholar
  50. 50.
    Wang LS, Huang HH, Lin TS, Huang BS, Chien KY. Malignant thymoma. Cancer 1992;70:443–450.PubMedCrossRefGoogle Scholar
  51. 51.
    Utsumi T, Hiroyuki S, Matsumara A, Maeda H, Ohta M, Tada H, et al. Stage III thymoma: relationship of local invasion to recurrence. J Thorac Cardiovasc Surg 2008;136:1481–1485.PubMedCrossRefGoogle Scholar
  52. 52.
    Cheng YJ. Videothoracoscopic resection of encapsulated thymic carcinoma: retrospective comparison of the results between thoracoscopy and open methods. Ann Surg Oncol 2008;15:2235–2238.PubMedCrossRefGoogle Scholar
  53. 53.
    Limmer KK, Kernstine KH. Minimally invasive and robotic assisted thymus resection. Thorac Surg Clin 2011;21:69–84.PubMedCrossRefGoogle Scholar
  54. 54.
    Venuta F, Anile M, Rendina EA, Vitolo D, De Giacomo T, Coloni GF. The value of transcapsular invasion in patients with thymoma. Arch Pathol Lab Med 2009;133:1364–1365.PubMedGoogle Scholar
  55. 55.
    Haniuda M, Miyazawa M, Yoshida K, Oguchi M, Sekai F, Izuno I, et al. Is postoperative radiotherapy for thymic carcinoma effective? Ann Surg 1996;224:219–224.PubMedCrossRefGoogle Scholar
  56. 56.
    Urgesi A, Monetti U, Rossi G, Ricardi U, Maggi G, Sannazzari GL. Aggressive treatment of intrathoracic recurrences in thymoma. Radiother Oncol 1992;24:221–225.PubMedCrossRefGoogle Scholar
  57. 57.
    D’Andrilli A, Ciccone AM, Ibrahim M, Venuta F, Rendina EA. A new technique for prosthetic reconstruction of the superior vena cava. J Thorac Cardiovasc Surg 2006;132:192–194.PubMedCrossRefGoogle Scholar
  58. 58.
    D’Andrilli A, Ibrahim M, Venuta F, De Giacomo T, Coloni GF, Rendina EA. Glutaraldehyde preserved autologous pericardium for patch reconstruction of the pulmonary artery and superior vena cava. Ann Thorac Surg 2005;80:357–358.PubMedCrossRefGoogle Scholar
  59. 59.
    Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA Thymoma. Ann Thorac Surg 2006;82:234–239.Google Scholar
  60. 60.
    Huang J, Rizk NP, Travis WD, Seshen VE, Bains MS, Dycoco J, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 2007;134:1477–1484.PubMedCrossRefGoogle Scholar
  61. 61.
    Lucchi M, Davini F, Ricciardi R, Duranti L, Boldrini L, Palmiero G, et al. Management of pleural recurrence after curative resection of thymoma. J Thorac Cardiovasc surg 2009;137:1185–1189.PubMedCrossRefGoogle Scholar
  62. 62.
    Yano M, Sasaki H, Yukiue H, Kawano O, Okuda K, Hikasaka Y, et al. Thymoma with dissemination: efficacy of microscopic total resection of disseminated nodules. World J Surg 2009;33:1425–1431.PubMedCrossRefGoogle Scholar
  63. 63.
    Ishikawa Y, Matsugama H, Nakahara R, Suzuki H, Ui A, Kondo T, et al. Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pleuropneumonectomy. Ann Thorac Surg 2009;88:952–957.PubMedCrossRefGoogle Scholar
  64. 64.
    Ruffini E, Filosso PL, Oliaro A. The role of surgery in recurrent thymic tumors. Thorac Surg Clin 2009;19:121–123.PubMedCrossRefGoogle Scholar
  65. 65.
    Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L, Levasseur P. Results of resection of recurrent thymomas. Ann Thorac Surg 1997;64:1593–1598.PubMedCrossRefGoogle Scholar
  66. 66.
    Rea F, Sartori F, Loy M, Calabrò F, Fornasiero A, Daniele O, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543–549.PubMedGoogle Scholar
  67. 67.
    Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatment. Ann Thorac Surg 2005;79:1840–1844.PubMedCrossRefGoogle Scholar
  68. 68.
    Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery and postoperative radiation therapy for invasive thymoma. Cancer 1991;68:706–713.PubMedCrossRefGoogle Scholar
  69. 69.
    Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy followed by surgical resection, radiation therapy and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369–379.PubMedCrossRefGoogle Scholar
  70. 70.
    Kunitoh H, Tamura T, Shibata T, Takeda K, Katakimi N, Nakagawa K, et al. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy in locally advanced thymoma: report of a Japan clinical oncology group trial (JCOG 9606). Br J Cancer 2010;103:6–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Hu E, Levine J. Chemotherapy of malignant thymoma: case report and review of the literature. Cancer 1986;57:1101–1104.PubMedCrossRefGoogle Scholar
  72. 72.
    Uematsu M, Kondo M. A proposal for treatment of invasive thymoma. Cancer 1986;58:1979–1984.PubMedCrossRefGoogle Scholar
  73. 73.
    Godel N, Boning L, Fredrick A, Halzel D, Hartenstein R, Wilmenns W. Chemotherapy of invasive thymoma: a retrospective study of 22 cases. Cancer 1989;63:1493–1500.CrossRefGoogle Scholar
  74. 74.
    Butler WM, Diehl LF, Taylor HG, Welz MD. Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy. Cancer 1982;50:419–422.PubMedCrossRefGoogle Scholar
  75. 75.
    Kosmidis PA, Iliopulos E, Penetea S. Combination chemotherapy with cyclophosphamide, adriamycin and vincristine in malignant thymoma and myasthenia gravis. Cancer 1988;61:1736–1740.PubMedCrossRefGoogle Scholar
  76. 76.
    Hemandez-Ilizaliturri FJ, Tan D, Cipolla D, Connoly G, Debb G, Ramnath N. Multimodality therapy for thymic carcinoma (TCA): results of a 30 year single institution experience. Am J Clin Oncol 2004;27:68–72.CrossRefGoogle Scholar
  77. 77.
    Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabrò F, et al. Chemotherapy for invasive thymoma: a 13-year experience. Cancer 1991;68:130–133.CrossRefGoogle Scholar
  78. 78.
    Loehrer PJ Sr, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston E, et al. Cisplatin, doxorubicin and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093–3099.PubMedGoogle Scholar
  79. 79.
    Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993;16:342–345.PubMedCrossRefGoogle Scholar
  80. 80.
    Loehrer PJ, Kim KM, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol 1994;12:1164–1168.PubMedGoogle Scholar
  81. 81.
    Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sehmond T, Van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study in the European Organization for Research and Treatment of Cancer? Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814–820.PubMedGoogle Scholar
  82. 82.
    Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green H, Thomes CR, et al. Combined etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: and intergroup trial. Cancer 2001;91:2010–2015.PubMedCrossRefGoogle Scholar
  83. 83.
    Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010;67:194–197.PubMedCrossRefGoogle Scholar
  84. 84.
    Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M. Treatment and prognosis of primary thymic carcinoma. J Surg Oncol 1993;52:255–258.PubMedCrossRefGoogle Scholar
  85. 85.
    Haniuda M, Kondo R, Numamami H, Makiuchi A, Machida E, Ameno J, et al. Recurrence of thymoma: clinicopathological features, reoperation and outcome. J Surg Oncol 2001;23:134–135.Google Scholar
  86. 86.
    Ferone D, van Hagen MP, Kwekkeboom DJ, Van Koetsveld PM, Mooy DM, Lichteiner-Kaligis E, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000;85:1719–1726.PubMedCrossRefGoogle Scholar
  87. 87.
    Lastoria S, Vergara E, Palmieri G, Acampa W, Varrilla P, Caracò C, et al. In vivo detection of malignant thymic masses by indium-111 DTPA D Phe 1 octreotide scintigraphy. J Nucl Med 1998;39:634–639.PubMedGoogle Scholar
  88. 88.
    Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002;94:1414–1420.PubMedCrossRefGoogle Scholar
  89. 89.
    Loehrer Pl, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 2004;15:293–299.Google Scholar
  90. 90.
    Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A, et al. Response of thymoma to cetuximab. Lancet Oncol 2007;8:449–450.PubMedCrossRefGoogle Scholar
  91. 91.
    Kurup A, Burns M, Dropcho S. Phase II study of gefitinib treatment in advanced thymic malignancies. J ClinOncol 2005;23;a7068.Google Scholar
  92. 92.
    Pao W, Wang TY, Riely GI, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLOS Med 2005;2:e17.PubMedCrossRefGoogle Scholar
  93. 93.
    Salter JT, Lewis D, Yiannoutsos C. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26:a8116.Google Scholar
  94. 94.
    Haluska P, Shaw H, Batzel GN. Phase I dose escalation study of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol 2007;25:a3586.Google Scholar
  95. 95.
    Bedano PM, Perkins S, Burns M. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;26:a19087.Google Scholar
  96. 96.
    Isambert N, Freyer G, Zanetta S. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008;26:a3599.Google Scholar
  97. 97.
    Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbu HNC, et al. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol 2009;48:619–621.PubMedCrossRefGoogle Scholar
  98. 98.
    Curran WJ Jr, Kornstein Ml, Brooks JJ, Turrisi AT 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 1988;6:1722–1727.PubMedGoogle Scholar
  99. 99.
    Urgesi A, Monetti U, Rossi G, Ricardi U, Casadio C. Role of radiation therapy in locally advanced thymoma. Radiother Oncol 1990;19:273–280.PubMedCrossRefGoogle Scholar
  100. 100.
    Uematsu M, Yoshida H, Kondo M, Itami J, Hatano K, Isobe K, et al. Entire hemithorax irradiation following complete resection in patients with stage II-lII invasive thymoma. Int J Radiat Oncol Biol Phys 1996;35:357–360.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2012

Authors and Affiliations

  • Federico Venuta
    • 1
    Email author
  • Erino A. Rendina
    • 1
  • Marco Anile
    • 1
  • Tiziano de Giacomo
    • 1
  • Domenico Vitolo
    • 1
  • Giorgio F. Coloni
    • 1
  1. 1.Cattedra di Chirurgia Toracica, Policlinico Umberto IUniversità di Roma SAPIENZARomeItaly

Personalised recommendations